Both human NMT isozymes, NMT1 and NMT2, are expressed in most tissues, and have been implicated in the development and progression of diseases including cancer (Selvakumar et al., 2007), epilepsy (Selvakumar et al., 2005), Alzheimer’s disease (Su et al., 2010), and Noonan-like syndrome (Cordeddu et al., 2009). Here, NMT1 is linked to early-onset autosomal dominant Alzheimer disease.